I 118th CONGRESS 1st Session H. R. 6749 IN THE HOUSE OF REPRESENTATIVES December 13, 2023 Ms. Clarke of New York (for herself, Mrs. Lesko , Ms. Blunt Rochester , Ms. Houlahan , Mr. Ryan , Ms. Wild , Ms. Lee of California , Mrs. Cammack , Ms. Velázquez , Mr. Posey , Ms. Sewell , Mr. Grijalva , Ms. Tlaib , Ms. Williams of Georgia , Mrs. Ramirez , Mr. Tonko , Ms. Norton , Mr. Nadler , Ms. Moore of Wisconsin , Mr. Davis of North Carolina , Ms. Porter , Mr. Green of Texas , Ms. Crockett , Mr. Allred , Mrs. Cherfilus-McCormick , Ms. Kelly of Illinois , Mr. Jackson of Illinois , Mr. Lawler , Mrs. Watson Coleman , Ms. Barragán , Ms. Caraveo , Mr. García of Illinois , Mr. Trone , Mr. Vargas , Mrs. Beatty , Mrs. Fletcher , Mr. Fitzpatrick , Ms. Kuster , Ms. Adams , Ms. Pingree , and Mr. Takano ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To require the Director of the National Institutes of Health to evaluate the results and status of completed and ongoing research related to menopause, perimenopause, or mid-life women’s health, to conduct and support additional such research, and for other purposes.

1. Short title This Act may be cited as the Menopause Research and Equity Act of 2023 . 2. Evaluation of completed and ongoing research related to menopause, perimenopause, or mid-life women’s health (a) In general The Director of the National Institutes of Health shall— (1) conduct an evaluation of— (A) the results of research related to menopause, perimenopause, or mid-life women’s health that is complete; (B) the status of such research that is ongoing; and (C) any gaps in knowledge and research on— (i) treatments for menopause-related symptoms; and (ii) the safety and effectiveness of treatments for menopause-related symptoms; and (2) as part of such evaluation, identify the total amount of funding allocated by the National Institutes of Health for the conduct or support of research related to menopause, perimenopause, or mid-life women’s health over the preceding 5 fiscal years. (b) Report; strategic plan Not later than 180 days after the date of enactment of this Act, the Director of the National Institutes of Health shall submit to the Congress— (1) a plan to perform the evaluation under subsection (a); and (2) a plan to develop a strategy, based on such evaluation, that will— (A) be designed and implemented by the Director in cooperation with a multidisciplinary group of health professionals including gynecologists, oncologists, endocrinologists, cardiologists, and neuroscientists; (B) include strategies to resolve the gaps in knowledge and research identified in the report; and (C) identify topics in need of further research relating to potential treatments for menopause-related symptoms. 3. Additional research related to menopause, perimenopause, or mid-life women’s health (a) Additional research (1) In general The Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, shall conduct or support research related to menopause, perimenopause, or mid-life women’s health. (2) Required elements The research required by paragraph (1) shall include— (A) research concerning causes, symptoms, and treatments for menopause, perimenopause, and other related mid-life women’s health issues; and (B) a multidisciplinary study of the effects of hormonal treatment for menopausal symptoms. 4. No additional funds authorized to be appropriated No additional funds are authorized to be appropriated to carry out this section, and this section shall be carried out using amounts otherwise available for such purpose.